trending Market Intelligence /marketintelligence/en/news-insights/trending/XSVefKvl-3JO9wXgPoM0hA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J seeks EU approval of Imbruvica-Rituxan combo as initial blood cancer therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


J&J seeks EU approval of Imbruvica-Rituxan combo as initial blood cancer therapy

Johnson & Johnson filed an application with the European Medicines Agency seeking approval of a combination of its drug Imbruvica and Roche Holding AG's Rituxan as a first-line treatment for a type of blood cancer.

The company's application is backed by data from a late-stage study that evaluated the combination therapy against the standard of care in 529 patients with previously untreated chronic lymphocytic leukemia.

CLL is a type of cancer that affects the white blood cells and occurs in the bone marrow.

Results from the study showed that the combination therapy proved to be better than a chemotherapy-based standard of care in extending the life-span of patients without the disease worsening.

North Chicago, Ill.-based AbbVie Inc. co-markets Imbruvica, or ibrutinib, in the U.S. with J&J's Janssen Pharmaceutical Ltd. The medication is currently approved for various blood cancer indications.